Compositions and methods for treating cancer via CD155 / TIGIT pathway and antagonists of TGF-β

摘要

The present disclosure relates to anti-CD155 [CD155, Nectin-like protein 5 (Nec1-5), Tage4, HVED, poliovirus receptor (PVR)] antibody or anti-TIGIT antibody [TIGIT (T cell immune receptor having Ig and ITIM domains) ), WUCAM (Washington University cell adhesion molecule), Vstm3 (V-set and transmembrane domain-containing protein 3), Vsig9 (V-set and immunoglobulin domain-containing protein 9)] and a TGFbeta1 antagonist. This effect is judged by increased production of IFN-gamma in human breast cancer cells. It is claimed that antibodies / CD155 or TIGIT) are used in combination with TGF-beta1 antagonists to treat patients with cancer.